Mark P. Labrecque

1.1k total citations
17 papers, 378 citations indexed

About

Mark P. Labrecque is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research. According to data from OpenAlex, Mark P. Labrecque has authored 17 papers receiving a total of 378 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 8 papers in Molecular Biology and 7 papers in Cancer Research. Recurrent topics in Mark P. Labrecque's work include Prostate Cancer Treatment and Research (9 papers), Cancer, Hypoxia, and Metabolism (6 papers) and Protein Degradation and Inhibitors (3 papers). Mark P. Labrecque is often cited by papers focused on Prostate Cancer Treatment and Research (9 papers), Cancer, Hypoxia, and Metabolism (6 papers) and Protein Degradation and Inhibitors (3 papers). Mark P. Labrecque collaborates with scholars based in United States, Canada and South Africa. Mark P. Labrecque's co-authors include Timothy V. Beischlag, Gratien G. Préfontaine, Peter S. Nelson, Ilsa M. Coleman, Mandeep Takhar, Colm Morrissey, Gary H. Perdew, Brett D. Hollingshead, Eva Corey and Michael Cox and has published in prestigious journals such as PLoS ONE, Cancer Research and Scientific Reports.

In The Last Decade

Mark P. Labrecque

17 papers receiving 376 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark P. Labrecque United States 11 175 128 90 85 47 17 378
Brandie N. Radde United States 12 194 1.1× 45 0.4× 78 0.9× 79 0.9× 47 1.0× 12 395
Ettickan Boopathi United States 15 205 1.2× 68 0.5× 97 1.1× 60 0.7× 8 0.2× 27 463
Jae Yeon Chun United States 10 180 1.0× 187 1.5× 135 1.5× 136 1.6× 14 0.3× 13 477
Tulika Tyagi United States 9 185 1.1× 34 0.3× 73 0.8× 50 0.6× 26 0.6× 15 333
İlhan Yaylım Türkiye 13 173 1.0× 44 0.3× 82 0.9× 77 0.9× 12 0.3× 59 438
Victor Okoh United States 8 198 1.1× 140 1.1× 58 0.6× 61 0.7× 17 0.4× 8 434
G Brun France 11 231 1.3× 64 0.5× 103 1.1× 102 1.2× 30 0.6× 21 460
Zhendong Chen China 6 115 0.7× 74 0.6× 100 1.1× 67 0.8× 29 0.6× 16 292
Elisabeth Specht Stovgaard Denmark 9 121 0.7× 48 0.4× 177 2.0× 94 1.1× 12 0.3× 14 437
Fadeke A. Agboke United States 12 176 1.0× 87 0.7× 88 1.0× 61 0.7× 9 0.2× 13 393

Countries citing papers authored by Mark P. Labrecque

Since Specialization
Citations

This map shows the geographic impact of Mark P. Labrecque's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark P. Labrecque with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark P. Labrecque more than expected).

Fields of papers citing papers by Mark P. Labrecque

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark P. Labrecque. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark P. Labrecque. The network helps show where Mark P. Labrecque may publish in the future.

Co-authorship network of co-authors of Mark P. Labrecque

This figure shows the co-authorship network connecting the top 25 collaborators of Mark P. Labrecque. A scholar is included among the top collaborators of Mark P. Labrecque based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark P. Labrecque. Mark P. Labrecque is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Labrecque, Mark P., Lisha G. Brown, Ilsa M. Coleman, et al.. (2023). Targeting the fibroblast growth factor pathway in molecular subtypes of castration‐resistant prostate cancer. The Prostate. 84(1). 100–110. 4 indexed citations
2.
Zhang, Ailin, Lisha G. Brown, Ilsa M. Coleman, et al.. (2023). Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers. Cancer Research Communications. 3(11). 2358–2374. 9 indexed citations
3.
Labrecque, Mark P., Lisha G. Brown, Ilsa M. Coleman, et al.. (2021). RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer. Cancer Research. 81(18). 4736–4750. 23 indexed citations
4.
Labrecque, Mark P., Lisha G. Brown, Ilsa M. Coleman, et al.. (2021). Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature. PLoS ONE. 16(1). e0245602–e0245602. 7 indexed citations
5.
Labrecque, Mark P., Joshi J. Alumkal, Ilsa M. Coleman, Peter S. Nelson, & Colm Morrissey. (2021). The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches. Endocrine Related Cancer. 28(8). T51–T66. 28 indexed citations
6.
Cardillo, Thomas M., Lisa S. Ang, Mark P. Labrecque, et al.. (2020). Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5–SN38 Antibody–drug Conjugate in Neuroendocrine Prostate Cancer. Clinical Cancer Research. 27(3). 759–774. 54 indexed citations
7.
8.
Lee, Martin, Christine Wang, Mark P. Labrecque, et al.. (2018). Expression of human inducible nitric oxide synthase in response to cytokines is regulated by hypoxia-inducible factor-1. Free Radical Biology and Medicine. 130. 278–287. 27 indexed citations
9.
Labrecque, Mark P., Lisha G. Brown, Ilsa M. Coleman, et al.. (2018). Abstract 1092: Defining the molecular phenotypes of metastatic castration-resistant prostate cancer sensitive to FGF pathway inhibition. Cancer Research. 78(13_Supplement). 1092–1092. 1 indexed citations
10.
Labrecque, Mark P., et al.. (2017). Retinoblastoma protein (Rb) links hypoxia to altered mechanical properties in cancer cells as measured by an optical tweezer. Scientific Reports. 7(1). 7833–7833. 9 indexed citations
11.
Labrecque, Mark P., Mandeep Takhar, Rebecca Nason, et al.. (2016). The retinoblastoma protein regulates hypoxia-inducible genetic programs, tumor cell invasiveness and neuroendocrine differentiation in prostate cancer cells. Oncotarget. 7(17). 24284–24302. 24 indexed citations
12.
13.
Labrecque, Mark P., et al.. (2014). Epigenetic Characterization of the Growth Hormone Gene Identifies SmcHD1 as a Regulator of Autosomal Gene Clusters. PLoS ONE. 9(5). e97535–e97535. 22 indexed citations
14.
Labrecque, Mark P., Mandeep Takhar, Julienne Jagdeo, et al.. (2014). A TRIP230-Retinoblastoma Protein Complex Regulates Hypoxia-Inducible Factor-1α-Mediated Transcription and Cancer Cell Invasion. PLoS ONE. 9(6). e99214–e99214. 8 indexed citations
15.
Labrecque, Mark P., Gratien G. Préfontaine, & Timothy V. Beischlag. (2013). The Aryl Hydrocarbon Receptor Nuclear Translocator (ARNT) Family of Proteins: Transcriptional Modifiers with Multi-Functional Protein Interfaces. Current Molecular Medicine. 13(7). 1047–1065. 37 indexed citations
16.
Labrecque, Mark P., Mandeep Takhar, Brett D. Hollingshead, et al.. (2012). Distinct Roles for Aryl Hydrocarbon Receptor Nuclear Translocator and Ah Receptor in Estrogen-Mediated Signaling in Human Cancer Cell Lines. PLoS ONE. 7(1). e29545–e29545. 39 indexed citations
17.
Perdew, Gary H., Brett D. Hollingshead, Brett C. DiNatale, et al.. (2010). Estrogen Receptor Expression Is Required for Low-Dose Resveratrol-Mediated Repression of Aryl Hydrocarbon Receptor Activity. Journal of Pharmacology and Experimental Therapeutics. 335(2). 273–283. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Brandie N. Radde Breakdown of academic impact, for papers by Ettickan Boopathi Breakdown of academic impact, for papers by Jae Yeon Chun Breakdown of academic impact, for papers by Tulika Tyagi Breakdown of academic impact, for papers by İlhan Yaylım Breakdown of academic impact, for papers by Victor Okoh Breakdown of academic impact, for papers by G Brun Breakdown of academic impact, for papers by Zhendong Chen Breakdown of academic impact, for papers by Elisabeth Specht Stovgaard Breakdown of academic impact, for papers by Fadeke A. Agboke
Rankless by CCL
2026